

INSIDE THIS ISSUE:

IQ11

Performance Highlights 1

Summary of Balance Sheets 3

Analyst Presentation 4

1Q11 Performance Highlights

During 1Q11, the Company and its subsidiaries recorded a consolidated net profit of Baht 836 million; an increase of Baht 82 million, or 11% yoy from 1Q10. The summarized 1Q11 consolidated performance is as follows:-

- ◆ Total operating income for 1Q11 were Baht 6,928 million, an increase of Baht 832 million or 14% from 1Q10 due mainly to the growth in revenue from hospital operations. During this quarter, Thai and international patients grew 11% and 8% yoy respectively resulting in the revenue proportion between Thai and international patients to be approximately 59%:41% in 1Q11. From type of patient perspective, inpatient revenues grew by 11% yoy while the outpatient revenues increased by 8% yoy. In addition, revenue from sales of goods and food were Baht 230 million, an increase from Baht 38 million in 1Q10, as a result of consolidation of revenue from sales of goods of A.N.B. Laboratories Company Limited for Baht 196 million since, during 4Q10, Royal Bangkok Healthcare Company Limited, the Company's subsidiary company, acquired 100% of A.N.B. Laboratories Company Limited, a manufacturer and distributor of medicines and pharmaceutical products.
- ◆ The Company and its subsidiaries reported cost of hospital operations and others of Baht 3,897 million in 1Q11, an increase by 17% yoy. An increase was due mainly to an increase in revenue from hospital operations together with the rise in doctor fee especially specialized doctors and rise in clinical staff expenses. In addition, the cost of hospital operations and others also included cost of good sold from A.N.B. Laboratories Company Limited. Since the revenue from hospital operations and revenue from sales of goods and foods grew at the slower pace than cost of hospital operations and others, the gross margin decreased from 44.9% in 1Q10 to 43.1% in 1Q11.

- ◆ The administrative expenses were Baht 1,296 million in IQ11, an increase by 15% yoy, due mainly to an increase in marketing expenses, advisory fee in relation to the merger with Phyathai hospital group and Paolo Memorial hospital group together with an increase in other administrative expenses. EBITDA; however, increased from Baht 1,649 million in IQ10 to Baht 1,736 million in IQ11, increased by 5% yoy. While the EBITDA margin decreased from 27.0% in IQ10 to 25.1% in IQ11.
- ◆ The depreciation and amortization expenses were Baht 540 million in IQ11, an increase by 1% yoy.
- ◆ Interest income was Baht 6 million, decreased by 54% yoy, as a result of a decrease in short-term investments.
- ◆ Share of income from investments in associated companies was Baht 83 million, increased by 29% yoy, due mainly to an increase in share of income from investment in Ramkhamhaeng Hospital Public Co., Ltd.
- ◆ Other items: - Finance expenses decreased to Baht 133 million or decreased by 14% yoy due mainly to repayment of long-term loans from financial institution together with the conversion of 27,000 units of convertible bonds in November 2010.
- ◆ Taxes in IQ11 were Baht 288 million, an increase from Baht 263 million in IQ10, due mainly to increase in pre-tax profit.

As a result, the Company and its subsidiaries recorded a consolidated net profit of Baht 836 million; an increase of Baht 82 million, or 11% yoy. Net profit margin slightly decreased from 12.2% in IQ10 to 11.9% in IQ11 and the basic earnings per share increased from Baht 0.62 in IQ10 to Baht 0.67 in IQ11 or grew 8% yoy.



Comprehensive income statements

<u>(Unit : THB mm)</u>	<u>IQ11</u>	<u>IQ10</u>	<u>% yoy</u>
Profit for the period	836	753	11%
Gain(Loss) on change in value of available-for-sale investments	490	(0)	N/A
Exchange differences	5	(19)	(128)%
Share of other comprehensive income from associated company	117	-	N/A
Total comprehensive income for the period	<u>1,448</u>	<u>734</u>	<u>97%</u>

Total comprehensive income for the period was Baht 1,448 million, an increase by 97% yoy from IQ10, mainly attributable to higher profit for the period as mentioned earlier together with a gain on change in value of available-for-sale investments of Baht 490 million for the investment in Bumrungrad Hospital Public Company Limited ("BH"). During IQ11, the Company had invested in BH for 103.83 million shares totaling Baht 3,456 million, representing 14.22% of the issued and paid-up capital of BH. In addition, the Company has recognized share of other comprehensive income from associated company of Baht 117 million which was mainly as a result of gain on change in value of available-for-sale investments of Ramkhamhaeng Hospital Public Co., Ltd.

Summary of Balance Sheets

(Unit : THB mm)	<u>Mar-11</u>	<u>Dec-10</u>	<u>Chg %</u>
Total Assets	34,634	32,197	8%
Total Liabilities	17,423	15,914	9%
Total equity attributable to company's shareholders	16,584	15,634	6%
Total shareholders' equity	17,211	16,283	6%

The consolidated financial position of the Company and its subsidiaries as of March 31, 2011 : The Company and its subsidiaries reported total assets of Baht 34,634 million, an increase of Baht 2,437 million or 8% from December 31, 2010, due mainly to an increase in other long-term investments which mainly were the investment in BH of Baht 3,456 million together with an increase in accounts receivable of Baht 357 million, netted with a decrease in short-term investments of Baht 1,737 million

Total consolidated liabilities as of March 31, 2011 were Baht 17,423 million, an increase of Baht 1,509 million or 9% from December 31, 2010, due mainly to issuance of debentures totaling Baht 3,495 million together with an increase in short-term loans from financial institutions of Baht 1,143 million, offset with repayment of maturing debentures for Baht 2,999 million. Total debt to equity remains unchanged at 0.7x as of December 31, 2010 and as of March 31, 2011 while net debt to equity increased slightly from 0.5x as of December 31, 2010 to 0.6x as of March 31, 2011

Total consolidated shareholders' equity (excluding equity attributable to non-controlling interests of subsidiaries) were Baht 16,584 million, increased by Baht 950 million or 6% from the year ended 2010. This is due mainly to the net profit during IQ11 together with an adjustment in fair value of investment of Baht 607 million, offset with the cumulative effect of change in accounting policy for employee benefits of Baht 497 million. For the first-time adoption of TAS 19 employee benefits, the Company elected to recognize the transitional liability, which exceeds the liability that would have been recognized at the same date under the previous accounting policy, through an adjustment to the beginning balance of retained earnings in IQ11.

Analyst Presentation



BDMS hosted the Analyst meeting for the IQ11 results on May 23, 2011. The meeting provided the investment community an opportunity to update the performance and address any questions or comment to the management. Participants are both buy-side and sell-side analysts, investors, stakeholders including, BDMS management, Khun Narumol Noi-Am, BDMS CFO and Ajaya Intaraprasong, BDMS Finance Director, Investor Relations.

Presentation material also posted on our website at www.bangkokhospital.com under investor relations.



Thailand



Overseas



Bangkok Dusit Medical Services Public Company Limited (SET Symbol : BGH) is the largest private hospital operator in Thailand in terms of patient services revenue and market capitalization with approximately THB 34.6 billion in assets as of March 2011. Bangkok Dusit Medical Services Public Company Limited ("BDMS") has 25 hospitals in Thailand and 2 hospitals in Cambodia. BDMS is focused on Bangkok and various high-growth markets in the Southern and Eastern regions of Thailand and overseas locations. The Company is committed to be the leading network healthcare provider by meeting the needs of Thai and foreign patients with high quality, internationally-accepted standards, and value for money services together with the state-of-the art medical technology.

Contact: Investor Relations
 Bangkok Dusit Medical Services Public Company Limited
 2 Soi Soonvijai 7, New Petchburi Road, Bangkok 10310 Thailand
 Tel +66(0)2755-1793
 Email investor@bangkokhospital.com